A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Cabazitaxel (Primary) ; Abiraterone; Enzalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 04 Dec 2017 Planned End Date changed from 1 Oct 2016 to 1 May 2020.
- 04 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated